These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29511993)

  • 1. Pulmonary Arterial Hypertension: Combination Therapy in Practice.
    Burks M; Stickel S; Galiè N
    Am J Cardiovasc Drugs; 2018 Aug; 18(4):249-257. PubMed ID: 29511993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
    Udeoji DU; Schwarz ER
    Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension.
    Hill NS; Cawley MJ; Heggen-Peay CL
    J Manag Care Spec Pharm; 2016 Mar; 22(3 Suppl A):S3-21. PubMed ID: 27003666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond a single pathway: combination therapy in pulmonary arterial hypertension.
    Sitbon O; Gaine S
    Eur Respir Rev; 2016 Dec; 25(142):408-417. PubMed ID: 27903663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary arterial hypertension: tailoring treatment to risk in the current era.
    Gaine S; McLaughlin V
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy in the management of pulmonary arterial hypertension.
    Buckley MS; Staib RL; Wicks LM
    Int J Clin Pract Suppl; 2013 May; (179):13-23. PubMed ID: 23578069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management.
    Burger CD; D'Albini L; Raspa S; Pruett JA
    Am J Manag Care; 2016 Jan; 22(1 Suppl):S3-15. PubMed ID: 26885569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
    Badesch DB; Abman SH; Ahearn GS; Barst RJ; McCrory DC; Simonneau G; McLaughlin VV;
    Chest; 2004 Jul; 126(1 Suppl):35S-62S. PubMed ID: 15249494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of pulmonary arterial hypertension with a focus on combination therapies.
    Benza RL; Park MH; Keogh A; Girgis RE
    J Heart Lung Transplant; 2007 May; 26(5):437-46. PubMed ID: 17449411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary hypertension in 2012: contemporary issues in diagnosis and management.
    Lau EM; Corte TJ
    Panminerva Med; 2012 Mar; 54(1):11-28. PubMed ID: 22278113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
    Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in pulmonary arterial hypertension: is this the new standard of care?
    Ruiz G; Besinque GM; Lickert CA; Raspa S
    Am J Manag Care; 2015 Jun; 21(8 Suppl):s151-61. PubMed ID: 26168371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin antagonism in pulmonary arterial hypertension.
    Lee SH; Channick RN
    Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.
    Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
    Kylhammar D; Persson L; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
    Small M; Piercy J; Pike J; Cerulli A
    Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy for the treatment of pulmonary arterial hypertension.
    Levinson AT; Klinger JR
    Ther Adv Respir Dis; 2011 Dec; 5(6):419-30. PubMed ID: 21849335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.